Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-022 in relapsed/refractory marginal zone lymphoma
CTR20190011Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in marginal zone B-cell lymphoma (MZL), sponsored by InnoCare Pharma. Started Jan 2019; status: completed.
02
Drugs
orelabrutinib
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20190011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190011.